No Data
No Data
Institute of Immunology Research: (Correction/numerical data correction) Partial correction of the "March 2024 term-end settlement report [Japan standard] (consolidated)."
The era of 5 million dementia patients has arrived, promising stocks and overall verification of social issues. <Stock Top Feature>
The second meeting of the conference for promoting dementia policies was held on May 8th, and it was estimated that the number of dementia patients would reach 5.231 million in 2030 (4.432 million in 2022). The "Basic Law on Dementia" was enacted in January of this year to realize a society in which people with dementia can live together, and discussions are underway to formulate a basic plan. However, to overcome the era of 5 million dementia patients, it is essential to utilize both policies and treatments, as well as technology. Therefore, this time, we focus on related stocks that confront social issues.
IMMUNO-BIOLOGICAL LABORATORIES: Financial results briefing materials for the fiscal year ending 2024/3 (42nd term)
IMMUNO-BIOLOGICAL LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Immuno Biological Labs Sees FY Net Y115.00M
Immuno-Biological Laboratories Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2025 Revenue Y925.00 mln Operating Profit Y120.
Classicom, Confidence I, etc.
<2351>ASJ upward revision, previous fiscal year operating profit forecast 102 million yen ← 80 billion yen <3286>Trust HD shareholder benefit plan newly established <3625> tech firm earnings forecast revision, current fiscal year sales forecast 5.00 billion yen ← 6.00 billion yen <3917>formulating a medium-term management plan involving iRidge from the fiscal year ending 25/3 to the fiscal year ending 27/3 <4165> Played revised upward, sales forecast for the current fiscal year ending 10.809 billion yen ← 10.666 billion yen <43
No Data